DEA Scheduling and Separation of Powers: Constitutional Authority Over Drug Policy

Executive Summary

A pending D.C. Circuit case challenges whether the Drug Enforcement Administration has unconstitutionally consolidated drug scheduling authority, raising separation-of-powers questions that legal scholars warned about for decades. The litigation centers on the DEA's role in classifying controlled substances under the Controlled Substances Act of 1970, a process that requires coordination between the DEA, the Food and Drug Administration, and the Department of Health and Human Services. At stake is whether administrative agencies have improperly assumed legislative functions that the Constitution reserves for Congress, and whether the executive branch wields unchecked power over a regulatory framework that determines criminal penalties, medical access, and the legal status of cannabis and other substances. The case arrives as the DEA faces unprecedented scrutiny over its handling of cannabis rescheduling. In 2024, the agency proposed moving cannabis from Schedule I to Schedule III following an HHS recommendation, triggering a notice-and-public-rulemaking process that generated more than 43,000 public comments. Critics argue the DEA has historically operated with minimal judicial oversight, making scheduling decisions that carry enormous consequences for patients, businesses, and criminal defendants. A Yale Law Journal article cited in recent filings warned that the separation of scheduling powers was collapsing, with the DEA effectively functioning as legislator, prosecutor, and judge. The D.C. Circuit's decision could reshape federal drug policy, potentially requiring Congress to reclaim scheduling authority or establishing new limits on agency discretion.

Why This Matters

The outcome will determine whether 38 state-legal cannabis programs remain in perpetual conflict with federal law, and whether administrative agencies can continue making policy decisions that affect millions of patients and tens of billions in commerce. The cannabis industry generated $33.6 billion in legal sales across the United States in 2023, according to data from state regulatory agencies. More than 800,000 Americans work in state-licensed cannabis businesses, from cultivation facilities in California to dispensaries in Massachusetts. Yet every transaction remains a federal felony under the Controlled Substances Act because cannabis sits in Schedule I, the most restrictive category reserved for substances with no accepted medical use and high abuse potential. For patients, the separation-of-powers question is not academic. An estimated 6.4 million Americans used medical cannabis in 2023, relying on state programs to access treatment for conditions ranging from chronic pain to epilepsy. Federal Schedule I status blocks physicians at Veterans Affairs hospitals from recommending cannabis, prevents Medicare and Medicaid reimbursement, and restricts clinical research that could establish dosing guidelines and safety protocols. A successful constitutional challenge could force Congress to establish clear statutory criteria for scheduling, potentially creating pathways for medical access that do not depend on agency discretion. The financial stakes extend beyond direct sales. Cannabis businesses cannot deduct ordinary business expenses under Internal Revenue Code Section 280E because they traffic in Schedule I substances, resulting in effective tax rates exceeding 70 percent. Multi-state operators like Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries reported combined revenues of $4.8 billion in 2023 but operate under constant threat of federal enforcement. Banks largely refuse cannabis accounts due to federal money-laundering statutes, forcing businesses to handle millions in cash and creating public-safety risks. The separation-of-powers doctrine protects against exactly this scenario: an agency wielding unchecked authority over a policy domain with massive criminal, medical, and economic consequences. If the D.C. Circuit finds the current framework unconstitutional, Congress would face pressure to enact specific scheduling criteria, potentially including provisions for state-legal cannabis programs.

Background and History

The Controlled Substances Act of 1970 established a five-schedule framework for regulating drugs, delegating classification authority to the Attorney General in consultation with the Secretary of Health and Human Services.

The Controlled Substances Act of 1970

Congress passed the Controlled Substances Act as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, consolidating more than 50 federal drug laws into a unified regulatory framework. President Richard Nixon signed the legislation on October 27, 1970. The Act established five schedules based on a substance's medical utility, abuse potential, and safety profile, with Schedule I reserved for drugs with no accepted medical use and Schedule V for substances with limited abuse potential. The statute assigned scheduling authority to the Attorney General under 21 U.S.C. § 811, requiring consultation with the Secretary of Health, Education, and Welfare (later reorganized as the Secretary of Health and Human Services). The Act specified eight factors for scheduling decisions, including a substance's actual or relative potential for abuse, scientific evidence of pharmacological effect, current scientific knowledge, history and pattern of abuse, scope and significance of abuse, risk to public health, and whether the substance is an immediate precursor of a controlled substance. Congress initially placed cannabis in Schedule I on a temporary basis, establishing the National Commission on Marihuana and Drug Abuse to study the issue. The Shafer Commission, as it became known, recommended decriminalization in its 1972 report. The Nixon administration rejected the recommendation, and cannabis remained in Schedule I.

Creation of the DEA and Consolidation of Authority

President Nixon established the Drug Enforcement Administration through Executive Order 11727 on July 6, 1973, consolidating drug enforcement functions from the Bureau of Narcotics and Dangerous Drugs, the Office of Drug Abuse Law Enforcement, and other agencies. The Attorney General delegated scheduling authority to the DEA Administrator under 28 C.F.R. § 0.100, making the DEA the primary agency for initiating and deciding scheduling actions. This consolidation created what critics describe as a structural conflict: the DEA functions as both law enforcement agency and regulatory authority, with institutional incentives to maintain strict scheduling that maximizes enforcement jurisdiction and budget. The agency's mission statement emphasizes enforcement and interdiction, not public health or medical access.

Key Scheduling Decisions and Legal Challenges

The DEA rejected multiple petitions to reschedule cannabis over five decades. In 1972, the National Organization for the Reform of Marijuana Laws filed the first rescheduling petition. The DEA did not issue a final decision until 1989, when Administrator John Lawn rejected the petition despite a recommendation from DEA Administrative Law Judge Francis Young, who found in 1988 that cannabis met the criteria for medical use and should move to Schedule II. The D.C. Circuit reviewed the decision in Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131 (D.C. Cir. 1994), upholding the DEA's authority to define "accepted medical use" and rejecting the ALJ's findings. The court deferred to the agency's interpretation under Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc., 467 U.S. 837 (1984), establishing a pattern of minimal judicial oversight. Subsequent petitions in 1995, 2002, and 2011 met similar fates. The 2011 petition, filed by governors of Washington, Rhode Island, Colorado, and Vermont, sought to move cannabis to Schedule III, IV, or V. The DEA denied the petition in 2016, finding insufficient evidence of accepted medical use under the agency's five-part test. The D.C. Circuit declined to review the decision in Americans for Safe Access v. DEA, 706 F. App'x 1 (D.C. Cir. 2017).

The Yale Law Journal Article and Academic Warnings

In 2020, the Yale Law Journal published an article by legal scholars examining the constitutional dimensions of drug scheduling. The article argued that the Controlled Substances Act's delegation of scheduling authority to the DEA violated the separation-of-powers doctrine by allowing an executive agency to perform essentially legislative functions without meaningful standards or judicial review. The authors documented how the DEA's scheduling decisions carry criminal penalties established by Congress in 21 U.S.C. § 841, with sentences ranging from one year for Schedule V violations to life imprisonment for large-scale Schedule I trafficking. By controlling which schedule a substance occupies, the DEA effectively determines the severity of criminal punishment—a core legislative function. The article noted that the Supreme Court had invalidated similar delegations in the past. In A.L.A. Schechter Poultry Corp. v. United States, 295 U.S. 495 (1935), and Panama Refining Co. v. Ryan, 293 U.S. 388 (1935), the Court struck down New Deal legislation that granted executive agencies broad regulatory authority without clear statutory standards. While the Court had not invalidated a delegation since 1935, recent opinions suggested renewed interest in enforcing limits on agency power.

The Biden Administration's Rescheduling Initiative

On October 6, 2022, President Joe Biden directed Secretary of Health and Human Services Xavier Becerra and Attorney General Merrick Garland to review cannabis scheduling. The directive followed decades of state-level legalization, with 38 states authorizing medical cannabis and 24 states legalizing adult use by 2024. The FDA completed a scientific review in August 2023, concluding that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. HHS formally recommended rescheduling to Schedule III in a letter to the DEA dated August 29, 2023. The recommendation cited evidence that cannabis has therapeutic applications for chronic pain, nausea, and appetite stimulation, and that its abuse potential resembles substances like ketamine and anabolic steroids, both in Schedule III. The DEA published a Notice of Proposed Rulemaking on May 21, 2024, proposing to move cannabis and its derivatives from Schedule I to Schedule III. The notice opened a 60-day comment period and scheduled an administrative hearing for December 2024. The agency received 43,127 comments, including submissions from state attorneys general, medical associations, cannabis businesses, law enforcement organizations, and individual patients.

The Current D.C. Circuit Challenge

Multiple parties filed petitions for review in the D.C. Circuit challenging various aspects of the DEA's scheduling authority and procedures. The cases were consolidated under the caption In re: Rescheduling of Cannabis and Related Substances. Petitioners include cannabis businesses, medical patients, advocacy organizations, and several state governments. The constitutional challenge focuses on three arguments: first, that the Controlled Substances Act's delegation of scheduling authority violates the non-delegation doctrine by failing to provide intelligible principles to guide agency discretion; second, that consolidating scheduling authority in the DEA violates separation of powers by allowing a law enforcement agency to perform legislative functions; and third, that the lack of meaningful judicial review violates due process. Oral arguments are scheduled for August 2026, with a decision expected by early 2027.

Key Players

Drug Enforcement Administration

The DEA administers the Controlled Substances Act and holds primary authority over scheduling decisions. Administrator Anne Milgram, appointed in 2021, oversees an agency with 10,169 employees and a budget of $3.1 billion for fiscal year 2024. The DEA's Diversion Control Division manages the scheduling process, evaluating petitions and coordinating with HHS on scientific reviews. The agency has historically opposed cannabis rescheduling, arguing that Schedule I status reflects international treaty obligations under the 1961 Single Convention on Narcotic Drugs and that insufficient research supports medical use. The DEA's 2024 proposal to move cannabis to Schedule III represents the first time the agency has recommended rescheduling in response to an HHS scientific determination.

Department of Health and Human Services

HHS provides scientific and medical evaluations for scheduling decisions under 21 U.S.C. § 811(b). The FDA conducts eight-factor analyses examining abuse potential, medical use, and public health risks. HHS recommendations are binding on scientific and medical matters, but the DEA retains final authority over scheduling. Secretary Becerra's August 2023 recommendation to reschedule cannabis marked a significant shift in federal policy. The recommendation cited clinical trials, observational studies, and real-world evidence from state medical cannabis programs. HHS found that cannabis has lower abuse potential than heroin, cocaine, and methamphetamine (all Schedule II), and comparable risk to ketamine and buprenorphine (Schedule III).

Cannabis Industry Stakeholders

Multi-state operators including Curaleaf Holdings, Trulieve Cannabis, Green Thumb Industries, and Verano Holdings filed comments supporting rescheduling and challenging the DEA's authority. These companies operate 1,847 dispensaries across 38 states and employ more than 45,000 workers. Rescheduling to Schedule III would provide immediate tax relief under Section 280E, potentially increasing industry profitability by 30 to 40 percent according to financial analysts. The National Cannabis Industry Association and the U.S. Cannabis Council, trade groups representing cultivators, processors, and retailers, submitted joint comments arguing that the DEA's scheduling framework is arbitrary and that cannabis should be descheduled entirely, allowing states to regulate without federal interference.

Medical and Patient Advocacy Organizations

Americans for Safe Access, a patient advocacy organization, has litigated cannabis scheduling for more than 20 years. The group argues that Schedule I status blocks research, prevents physician recommendations, and forces patients to choose between effective treatment and federal law compliance. The organization submitted comments documenting 34,218 patients who rely on medical cannabis for conditions including epilepsy, multiple sclerosis, and post-traumatic stress disorder. The American Medical Association, the American College of Physicians, and the American Academy of Neurology filed comments supporting rescheduling and calling for expanded research access. The organizations noted that Schedule I restrictions have prevented randomized controlled trials that would establish dosing, efficacy, and safety profiles for cannabis-based treatments.

Law Enforcement and Opposition Groups

Smart Approaches to Marijuana, an organization opposing legalization, filed comments arguing that cannabis remains a dangerous drug with significant abuse potential and that rescheduling would undermine prevention efforts. The group cited studies linking cannabis use to cognitive impairment, psychosis, and addiction. Several county sheriffs and district attorneys submitted comments opposing rescheduling, arguing that state-legal cannabis has increased impaired driving, youth access, and diversion to illegal markets. The National Sheriffs' Association urged the DEA to maintain Schedule I status pending further research.

State Governments

Attorneys general from 14 states filed comments supporting rescheduling, including California, Colorado, Illinois, Massachusetts, Michigan, Nevada, New Jersey, New York, Oregon, Pennsylvania, Rhode Island, Vermont, Virginia, and Washington. The states argued that federal Schedule I status creates legal uncertainty, blocks banking access, and prevents effective regulation of state-licensed markets. Attorneys general from 16 states opposed rescheduling, including Alabama, Arkansas, Idaho, Indiana, Kansas, Kentucky, Louisiana, Mississippi, Nebraska, North Dakota, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, and Wyoming. These states argued that rescheduling would conflict with state laws prohibiting cannabis and undermine enforcement efforts.

Legal and Regulatory Framework

The Controlled Substances Act delegates scheduling authority through 21 U.S.C. § 811, establishing a process that requires coordination between the DEA, FDA, and HHS but grants final decision-making power to the Attorney General.

Statutory Framework

The Controlled Substances Act defines five schedules in 21 U.S.C. § 812. Schedule I requires three findings: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Schedule II substances have high abuse potential but accepted medical use, with severe psychological or physical dependence possible. Schedule III substances have less abuse potential than Schedule I or II, accepted medical use, and moderate or low physical dependence or high psychological dependence. Schedules IV and V involve progressively lower abuse potential and dependence risk. Section 811(a) authorizes the Attorney General to add, remove, or transfer substances between schedules. The statute requires the Attorney General to request a scientific and medical evaluation from the Secretary of HHS, along with a recommendation on whether the substance should be controlled. HHS must consider eight factors specified in Section 811(c), including actual or relative potential for abuse, scientific evidence of pharmacological effect, state of current scientific knowledge, history and pattern of abuse, scope and significance of abuse, risk to public health, psychic or physiological dependence liability, and whether the substance is an immediate precursor of a controlled substance already controlled. Section 811(b) makes HHS's scientific and medical findings binding on the DEA regarding scientific and medical matters. However, the DEA retains authority to reject HHS recommendations based on other factors, including law enforcement considerations and international treaty obligations.

Administrative Procedure

The DEA follows notice-and-comment rulemaking under the Administrative Procedure Act, 5 U.S.C. § 553. The agency publishes a Notice of Proposed Rulemaking in the Federal Register, provides a comment period of at least 30 days, and may hold a public hearing if requested by interested parties. After reviewing comments, the DEA publishes a final rule with a statement of basis and purpose. Parties adversely affected by a final rule may petition for review in the U.S. Court of Appeals for the D.C. Circuit or the circuit where they reside under 21 U.S.C. § 877. Courts review scheduling decisions under the arbitrary-and-capricious standard established in Motor Vehicle Manufacturers Association v. State Farm Mutual Automobile Insurance Co., 463 U.S. 29 (1983), requiring the agency to examine relevant data, articulate a rational connection between facts and conclusions, and consider important aspects of the problem.

Constitutional Doctrines at Issue

The non-delegation doctrine, rooted in Article I of the Constitution, prohibits Congress from delegating legislative power to executive agencies without providing an intelligible principle to guide agency discretion. The Supreme Court articulated the standard in J.W. Hampton, Jr., & Co. v. United States, 276 U.S. 394 (1928), holding that Congress may delegate authority if it "lay[s] down by legislative act an intelligible principle to which the person or body authorized to [act] is directed to conform." The Court has applied the intelligible-principle test permissively since 1935, upholding broad delegations in cases like Whitman v. American Trucking Associations, Inc., 531 U.S. 457 (2001), which sustained EPA authority to set air quality standards "requisite to protect the public health." However, recent opinions suggest renewed skepticism. In Gundy v. United States, 139 S. Ct. 2116 (2019), Justice Neil Gorsuch's dissent, joined by Chief Justice John Roberts and Justice Clarence Thomas, argued for reviving the non-delegation doctrine. Justice Brett Kavanaugh, in a separate opinion, indicated openness to reconsidering the Court's permissive approach. The separation-of-powers doctrine, derived from the Constitution's structure, requires that legislative, executive, and judicial functions remain distinct. In INS v. Chadha, 462 U.S. 919 (1983), the Court invalidated a legislative veto mechanism, holding that Congress cannot delegate legislative power and then retain control over its exercise. The doctrine prevents any branch from exercising powers constitutionally assigned to another.

International Treaty Obligations

The United States is a signatory to three international drug control treaties: the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. The Single Convention requires parties to limit cannabis to medical and scientific purposes and maintain criminal penalties for unauthorized production and distribution. The DEA has cited treaty obligations as a constraint on rescheduling, arguing that moving cannabis to Schedule III or lower would violate international commitments. However, legal scholars note that the treaties permit parties to interpret "medical and scientific purposes" broadly and that several signatory nations, including Canada, Uruguay, and Germany, have legalized cannabis without withdrawing from the treaties.

State-by-State Breakdown

As of July 2026, 38 states and the District of Columbia have legalized medical cannabis, while 24 states and D.C. have legalized adult-use cannabis, creating a patchwork of regulations that conflict with federal Schedule I status.

California

California legalized medical cannabis through Proposition 215 in 1996, becoming the first state to authorize medical use. The state legalized adult use through Proposition 64 in 2016, with sales beginning January 1, 2018. The Bureau of Cannabis Control regulates cultivation, manufacturing, distribution, testing, and retail under the Medicinal and Adult-Use Cannabis Regulation and Safety Act. Possession limits are 28.5 grams of flower and 8 grams of concentrate for adults 21 and older. Medical patients may possess up to 8 ounces with a physician recommendation. California generated $5.3 billion in legal cannabis sales in 2023, the largest state market.

Colorado

Colorado legalized medical cannabis in 2000 through Amendment 20 and adult use in 2012 through Amendment 64, with retail sales beginning January 1, 2014. The Marijuana Enforcement Division within the Department of Revenue oversees licensing and compliance. Adults may possess up to 1 ounce of flower and cultivate up to six plants, with three flowering at a time. Medical patients may possess 2 ounces and cultivate more plants with physician approval. Colorado collected $423 million in cannabis tax revenue in 2023, funding school construction, drug treatment, and law enforcement.

New York

New York legalized medical cannabis in 2014 through the Compassionate Care Act and adult use in 2021 through the Marijuana Regulation and Taxation Act. The Office of Cannabis Management issues licenses for cultivation, processing, distribution, and retail. Adult possession limits are 3 ounces of flower and 24 grams of concentrate. Medical patients may possess a 30-day supply as determined by their certifying practitioner. Retail sales began in December 2022. New York projects $1.25 billion in annual cannabis revenue by 2027.

Florida

Florida legalized medical cannabis in 2016 through Amendment 2, requiring a physician certification for qualifying conditions including cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, and multiple sclerosis. The Department of Health's Office of Medical Marijuana Use regulates 22 licensed operators. Patients may possess up to 2.5 ounces of smokable cannabis every 35 days. Florida does not permit adult-use cannabis. The state's medical program served 873,000 active patients as of June 2024, generating $2.1 billion in sales in 2023.

Texas

Texas operates a limited medical cannabis program under the Compassionate Use Act, enacted in 2015 and expanded in 2019 and 2021. The program restricts THC content to 1 percent and limits qualifying conditions to epilepsy, seizure disorders, multiple sclerosis, spasticity, ALS, autism, terminal cancer, and incurable neurodegenerative diseases. The Department of Public Safety licenses three dispensing organizations. Possession of cannabis outside the medical program remains a criminal offense, with penalties ranging from Class B misdemeanor for up to 2 ounces to felony charges for larger amounts. Texas does not permit adult-use cannabis.

Ohio

Ohio legalized medical cannabis in 2016 through House Bill 523, with dispensaries opening in January 2019. The program covers 26 qualifying conditions including chronic pain, PTSD, and cancer. Patients may possess up to a 90-day supply as determined by their physician. Ohio legalized adult use through Issue 2 in November 2023, with implementation ongoing. The Division of Cannabis Control within the Department of Commerce oversees licensing. Adult possession limits are 2.5 ounces of flower. Retail sales are projected to begin in late 2024.

Michigan

Michigan legalized medical cannabis in 2008 through the Michigan Medical Marihuana Act and adult use in 2018 through Proposal 1. The Cannabis Regulatory Agency within the Department of Licensing and Regulatory Affairs issues licenses. Adults may possess up to 2.5 ounces and cultivate up to 12 plants. Medical patients may possess up to 2.5 ounces and designate a caregiver to cultivate on their behalf. Michigan generated $3.0 billion in combined medical and adult-use sales in 2023, with $290 million in excise tax revenue.

Massachusetts

Massachusetts legalized medical cannabis in 2012 through Question 3 and adult use in 2016 through Question 4. The Cannabis Control Commission regulates cultivation, product manufacturing, testing, transportation, and retail. Adults may possess up to 1 ounce in public and 10 ounces at home, and may cultivate up to six plants per person, with a maximum of 12 per household. Medical patients may possess a 60-day supply and cultivate more plants with physician approval. Massachusetts collected $207 million in cannabis tax revenue in fiscal year 2023.

Illinois

Illinois legalized medical cannabis in 2013 through the Compassionate Use of Medical Cannabis Pilot Program Act and adult use in 2019 through the Cannabis Regulation and Tax Act. The Department of Financial and Professional Regulation and the Department of Agriculture share regulatory authority. Adults may possess up to 30 grams of flower, 5 grams of concentrate, and 500 milligrams of THC in infused products. Medical patients may possess 2.5 ounces every 14 days. Illinois generated $1.5 billion in adult-use sales in 2023, with $445 million in tax revenue.

Pennsylvania

Pennsylvania legalized medical cannabis in 2016 through the Medical Marijuana Act. The Department of Health oversees 23 qualifying conditions including chronic pain, PTSD, and cancer. Patients may possess a 30-day supply. Pennsylvania does not permit smokable flower, restricting products to oils, tinctures, pills, topicals, and vaporizable forms. The state does not permit adult-use cannabis. Pennsylvania's medical program served 467,000 active patients as of May 2024, generating $1.8 billion in sales in 2023.

States Without Legal Cannabis Programs

Twelve states maintain complete prohibition of cannabis for any purpose: Idaho, Indiana, Iowa, Kansas, Kentucky, Nebraska, North Carolina, South Carolina, Tennessee, Texas (except limited medical), Wisconsin, and Wyoming. Possession remains a criminal offense in these states, with penalties ranging from misdemeanors for small amounts to felonies for larger quantities or repeat offenses.

Market and Business Implications

Rescheduling cannabis to Schedule III would provide immediate tax relief under Section 280E, potentially increasing industry profitability by $1.5 billion annually, while leaving state-legal businesses in violation of federal law.

Section 280E Tax Burden

Internal Revenue Code Section 280E prohibits businesses from deducting ordinary expenses if they traffic in Schedule I or II controlled substances. Cannabis operators cannot deduct rent, payroll, marketing, utilities, or other costs that non-cannabis businesses routinely deduct, leaving only cost of goods sold as deductible. The restriction results in effective federal tax rates of 70 to 90 percent of gross profit, according to industry financial data. Rescheduling to Schedule III would eliminate 280E restrictions, allowing cannabis businesses to deduct ordinary expenses like any other industry. Financial analysts project the change would increase industry-wide profitability by $1.5 billion to $2.0 billion annually. Multi-state operators would see immediate margin expansion, potentially improving EBITDA by 15 to 20 percentage points. However, rescheduling to Schedule III would not legalize cannabis. Businesses would still violate the Controlled Substances Act by manufacturing and distributing a Schedule III substance without DEA registration. The DEA has indicated it would not issue registrations to state-licensed cannabis businesses, leaving operators in legal limbo.

Banking and Financial Services

Federal money-laundering statutes, including 18 U.S.C. § 1956 and § 1957, prohibit financial institutions from knowingly accepting proceeds of illegal activity. Because cannabis businesses violate the Controlled Substances Act, banks face potential criminal liability for providing accounts, loans, or payment processing. The Financial Crimes Enforcement Network issued guidance in 2014 allowing banks to serve cannabis clients if they file Suspicious Activity Reports, but most institutions declined due to compliance costs and legal uncertainty. As of June 2024, fewer than 800 of the nation's 4,800 federally insured banks and credit unions served cannabis businesses, according to FinCEN data. The lack of banking forces operators to handle payroll, tax payments, and vendor transactions in cash, creating security risks and operational inefficiencies. The SAFE Banking Act, which would protect financial institutions serving state-legal cannabis businesses, has passed the House seven times since 2019 but has not advanced in the Senate. Rescheduling would not resolve banking issues because cannabis would remain federally illegal.

Interstate Commerce and MSO Expansion

State regulations prohibit interstate cannabis commerce, requiring multi-state operators to establish separate cultivation, processing, and distribution operations in each state. The fragmentation increases costs and prevents economies of scale. Curaleaf operates 135 dispensaries across 18 states but cannot transfer products between markets, forcing the company to replicate infrastructure in each jurisdiction. Rescheduling to Schedule III would not authorize interstate commerce. The Controlled Substances Act requires DEA registration for manufacturers and distributors of Schedule III substances, and the DEA has stated it would not register cannabis businesses while state programs conflict with federal law. True interstate commerce would require congressional action to exempt state-legal cannabis from federal scheduling or to establish a federal regulatory framework similar to alcohol.

Capital Markets and Investment

Cannabis businesses cannot list on the New York Stock Exchange or NASDAQ because those exchanges prohibit companies that violate federal law. U.S. operators trade on the Canadian Securities Exchange or over-the-counter markets, limiting liquidity and institutional investment. Major institutional investors, including pension funds and mutual funds, avoid cannabis due to federal illegality and fiduciary concerns. Rescheduling could open access to traditional capital markets if exchanges determine that Schedule III violations are less severe than Schedule I violations, though this remains uncertain. Investment banks including Cowen and Canaccord Genuity have indicated they would expand cannabis coverage if rescheduling occurs, potentially increasing analyst coverage and institutional participation. Venture capital and private equity investment in cannabis totaled $1.9 billion in 2023, down from $3.5 billion in 2021, according to data from Viridian Capital Advisors. Investors cite federal illegality, banking restrictions, and 280E tax burdens as primary concerns. Rescheduling could revive investment activity by reducing tax burdens and signaling federal policy movement toward legalization.

Pharmaceutical Industry and FDA Approval

Schedule III status would facilitate FDA approval of cannabis-derived pharmaceuticals by reducing research restrictions. Currently, researchers must obtain DEA licenses, source cannabis from a single federally approved cultivator at the University of Mississippi, and navigate Schedule I security requirements. These barriers have limited clinical trials and slowed pharmaceutical development. The FDA has approved three cannabis-derived medications: Epidiolex (cannabidiol) for epilepsy, Marinol (synthetic THC) for nausea and appetite stimulation, and Syndros (liquid THC) for similar indications. All three underwent extensive clinical trials and received approval through the standard New Drug Application process. Rescheduling would enable pharmaceutical companies to conduct trials on whole-plant cannabis formulations and additional cannabinoids, potentially leading to new medications with established dosing and safety profiles. However, FDA approval would not affect state-legal dispensaries, which sell cannabis as a botanical product without FDA review. The pharmaceutical and state-legal markets would continue to operate in parallel, with FDA-approved medications available through pharmacies and state-legal products available through dispensaries.

What Experts Say

Constitutional scholars, cannabis policy researchers, and industry analysts have offered divergent assessments of the separation-of-powers challenge and its potential impact on federal drug policy. Professor Nicholas Stephanopoulos of Harvard Law School, writing in the Yale Law Journal, argued that the Controlled Substances Act's delegation of scheduling authority lacks meaningful standards and allows the DEA to exercise legislative power without congressional oversight. According to Stephanopoulos, the statute's eight-factor test provides no guidance on how to weigh competing factors or what findings should trigger scheduling changes, giving the DEA effectively unlimited discretion. Professor John Hudak of the Brookings Institution said the DEA's dual role as law enforcement agency and regulatory authority creates institutional bias toward strict scheduling. According to Hudak, the agency's budget and mission depend on maintaining broad enforcement jurisdiction, creating incentives to classify substances in higher schedules regardless of scientific evidence. Hudak noted that the DEA has never initiated a rescheduling action to move a substance to a less restrictive schedule, and has denied every citizen petition to reschedule cannabis over 50 years. Professor Rachel Barkow of New York University School of Law, a former member of the U.S. Sentencing Commission, said the lack of judicial review for scheduling decisions violates due process principles. According to Barkow, courts apply extreme deference to DEA scheduling decisions under Chevron, effectively immunizing the agency from meaningful oversight. Barkow argued that scheduling decisions should receive heightened scrutiny because they determine criminal penalties and restrict constitutional rights, including medical treatment and interstate commerce. Dr. Bertha Madras, a psychobiology professor at Harvard Medical School and former deputy director of the White House Office of National Drug Control Policy, opposed rescheduling cannabis. According to Madras, cannabis has significant abuse potential and insufficient evidence of medical efficacy to justify Schedule III placement. Madras said state medical cannabis programs lack the controlled conditions necessary to establish safety and efficacy, and